Abstract
Thirty secnidazole derivatives have been synthesized and evaluated for Helicobacter pylori (H. Pylori) urease inhibitory activities and anti-inflammatory activities. All of them were reported for the first time. Their chemical structures were characterized by 1H NMR, 13C NMR, MS, and elemental analysis. Compound 5a, 6c and 8c showed the most potent urease inhibitory activities and anti-inflammatory activities with IC50 values of 1.7 μM, 1.0 μM, 2.0 μM and inhibition of 62.60%, 59.54%, 71.76%, respectively. Docking simulation was performed to position compound 6c into the urease active site to determine the probable binding model. Compound 5a, 6c and 8c with potent inhibitory activity against H. pylori may be potential antibacterial agents.
Keywords: Urease inhibitors, Helicobacter pylori, secnidazole derivatives, salicyclic acid derivatives, anti-inflammatory activites, docking, antibacterial agent, urea hydrolase, gastroduodenal diseases, living organisms
Current Bioactive Compounds
Title: The Synthesis, Structure and Activity Evaluation of Secnidazole Derivatives as Helicobacter pylori Urease Inhibitors
Volume: 7 Issue: 4
Author(s): Xi-Shou Huang, Kai Liu, Yong Yin, Wan-Mei Li, Wei Ran, Man Duan, Li-Sheng Wang and Hai-Liang Zhu
Affiliation:
Keywords: Urease inhibitors, Helicobacter pylori, secnidazole derivatives, salicyclic acid derivatives, anti-inflammatory activites, docking, antibacterial agent, urea hydrolase, gastroduodenal diseases, living organisms
Abstract: Thirty secnidazole derivatives have been synthesized and evaluated for Helicobacter pylori (H. Pylori) urease inhibitory activities and anti-inflammatory activities. All of them were reported for the first time. Their chemical structures were characterized by 1H NMR, 13C NMR, MS, and elemental analysis. Compound 5a, 6c and 8c showed the most potent urease inhibitory activities and anti-inflammatory activities with IC50 values of 1.7 μM, 1.0 μM, 2.0 μM and inhibition of 62.60%, 59.54%, 71.76%, respectively. Docking simulation was performed to position compound 6c into the urease active site to determine the probable binding model. Compound 5a, 6c and 8c with potent inhibitory activity against H. pylori may be potential antibacterial agents.
Export Options
About this article
Cite this article as:
Huang Xi-Shou, Liu Kai, Yin Yong, Li Wan-Mei, Ran Wei, Duan Man, Wang Li-Sheng and Zhu Hai-Liang, The Synthesis, Structure and Activity Evaluation of Secnidazole Derivatives as Helicobacter pylori Urease Inhibitors, Current Bioactive Compounds 2011; 7 (4) . https://dx.doi.org/10.2174/157340711798375868
DOI https://dx.doi.org/10.2174/157340711798375868 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Three-dimensional Printing-Driving Liver Therapies
Current Medicinal Chemistry Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Current Drug Targets Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA Particle Design of Membrane Emulsification for Protein Drug and Vaccine Delivery
Current Pharmaceutical Design Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules
Current Topics in Medicinal Chemistry Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer
Current Pharmaceutical Design Harnessing the Power of Light to Treat Staphylococcal Infections Focusing on MRSA
Current Pharmaceutical Design Prediction of Biological Activity Spectra for Substances: Evaluation on the Diverse Sets of Drug-Like Structures
Current Medicinal Chemistry Selective Inhibition of Osteoclast Vacuolar H+-ATPase
Current Pharmaceutical Design Anthraquinones: Analytical Techniques as a Novel Tool to Investigate on the Triggering of Biological Targets
Current Drug Targets In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Selected Attributes of Polyphenols in Targeting Oxidative Stress in Cancer
Current Topics in Medicinal Chemistry